Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma

• US 20030176356A1
• Filed: 04/24/2002
• Published: 09/18/2003
• Est. Priority Date: 04/24/2001
• Status: Abandoned Application

• Current Assignee: Univ. Of N TX Health Science Center
• Original Assignee: University of North Texas Health Science Center (University of North Texas)
• Inventors: Dibas, Adnan, Stokely, Martha E., Prasanna, Ganesh, Yorio, Thomas
• Application Number:
  US10/131,787
• Publication Number:
  US 20030176356A1
• Time in Patent Office: Days
• US Class Current: 514/17
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

A pharmaceutical composition, containing a therapeutically effective amount of an endothelin (“ET”) antagonists and/or an endothelin-converting enzyme (“ECE”) inhibitors and a pharmaceutically acceptable carrier. The pharmaceutical composition is useful for treating normal-tension and primary open-angle glaucoma and prevents optic nerve damage and retinal ganglion cell death associated with these ocular diseases.

Claims

1. A method for treating an ocular disease or damage thereof in an animal, comprising administering to the animal, a composition containing an effective amount of an endothelin (“

ET”

) antagonist in a pharmaceutically acceptable vehicle, wherein the ocular disease or damage is selected from the group consisting of ischemic retinopathies or optic neuropathies, commotio retinae, glaucoma, macular degeneration, retinitis pigmentosa, retinal detachment, retinal tears or holes, diabetic retinopathy, and iatrogenic retinopathy.

2. The method of claim 1, wherein the ocular disease is glaucoma.

3. The method of claim 1, wherein the ET antagonist comprises 4-tert-butyl-N-[6-(2-hydroxy-ethoxy-5-2methoxy-phenoxy-[2,2′

]-bipyrimidin-4-yl]-benzenesulfonamide monohydrate.

4. The method of claim 1, wherein the ET antagonist comprises N-Acetyl-β

-Phenyl-D-Phe-Leu-Asp-Ile-Ile-Trp, wherein Phe is pheylalanine, Leu is leucine, Asp is aspartic acid, Ile is isoleucine, and Trp is tryptophan.

5. The method of claim 1, wherein the ET antagonist comprises N-Acetyl-α

-[10,11-Dihydro-5H-dibenzo[a,d]cycloheptadien-5-yl]-D-Gly-Leu-Asp-Ile-Ile-Trp, wherein Gly is glycine, Leu is leucine, Asp is aspartic acid, Ile is isoleucine, and Trp is tryptophan.

6. The method of claim 1, wherein the ET antagonist comprises a compound with a formula of:

7. The method of claim 1, wherein the ET antagonist comprises a compound with a formula of:

8. The method of claim 1, wherein the ET antagonist comprises a compound with a formula of:

9. The method of claim 1, wherein the ET antagonist comprises N—

C is-2-6-Dimethyliperidinocarbonyl-L-gamma-methyleucyl-D-1-methylcarbonyl-tryptophanyl-D-Ile, wherein Ile is isoleucine.

10. The method of claim 1, wherein the ET antagonist comprises Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp, wherein Cys is cystine, Val is valine, Tyr is tyrosine, Phe is Phenylalanine, His is histidine, Leu is leucine, Asp is asoartuc acid, Ile is isoleucine, and Trp is tryptophan.

11. The method of claim 1, wherein the ET antagonist comprises a compound with a formula of:

12. The method of claim 1, wherein the ET antagonist comprises a compound with a formula of:

13. The method of claim 1, wherein the ET antagonist comprises (N,N-hexamethylene)-carbamoyl-Leu-D-Trp(CHO)-D-Trp, wherein Leu is leucine, Asp is aspartic acid, Ile is isoleucine, and Trp is tryptophan.

14. The method of claim 1, wherein the ET antagonist comprises c(D Trp-DAsp-Pro-DVal-Leu), wherein Asp is aspartic acid, Pro is proline, Val is valine, Leu is leucine, and Trp is tryptophan.

15. The method of claim 1, wherein the ET antagonist comprises N-cis-2,6-dimethylpiperidinocarbonyl-L-g-methyl-Leu-D-1-methoxycarbonyl-Trp-D-Nle and functions to inhibit an ET receptor, wherein Leu is leucine, Trp is tryptophan, and Nle is norleucine.

16. The method of claim 1, whereby administering the effective amount of one the ET antagonist is selected from a group consisting of systemic delivery, topical delivery, intraocular injection, intraocular perfusion, and retrobulbar injection.

17. The method of claim 1, whereby administering the effective amount of one the ET antagonist is selected from a group consisting of retrobulbar injection, intracameral delivery, intravitreal delivery.

18. A method for treating ocular disease or damage thereof in an animal, comprising administering to the animal, a composition containing an effective amount of an endothelin-converting-enzyme (“

ECE”

) inhibitor in a pharmaceutically acceptable vehicle, wherein the ocular disease or damage is selected from the group consisting of ischemic retinopathies or optic neuropathies, commotio retinae, glaucoma, macular degeneration, retinitis pigmentosa, retinal detachment, retinal tears or holes, diabetic retinopathy, and iatrogenic retinopathy.

19. The method of claim 18, wherein the ocular disease or damage is glaucoma.

20. The method of claim 18, wherein the ECE inhibitor comprises an aminophosphonate.

21. The method of claim 18, wherein the ECE inhibitor comprises a daleformis wherein the daleformis comprises an extract from a root of a Dalea filiciformis snader fabacae containing a compound with a general structure of:

22. The method of claim 18, wherein the ECE inhibitor comprises a halistanol disulfate B, wherein the halistanol disulfate B comprises a sterol sulfate isolated from a pacharella sponge, wherein the sterol sulfate has a general structure of:

23. The method of claim 18, wherein the ECE inhibitor comprises a hydroxamic acid, wherein the hydroxamic acid is selected from a group consisting of:

(a) N-[2-[(hydroxyamino)carbonyl]-3-methylbutanoyl]-L-asparagine;

(b) N-[2-[(hydroxyamino)carbonyl]-3-methyl-1-oxobutyl]-β

-aline;

(c) N-[2-[(hydroxyamino)carbonyl]-3-methylbutanoyl]-L-tryptophan;

(d) N-[2-[(hydroxyamino)carbonyl]-3-methylpentanoyl]-L-tryptophan; and

(e) N-[2-[(hydroxyamino)carbonyl]-3-methylbutanoyl]-L-glycine.

24. The method of claim 18, wherein the ECE inhibitor is a phosphoramidon and is N-a-Rhamonopyranosyloxyhydroxyphosphinyl-Leu-Trp, wherein Leu is leucine and Trp is tryptophan.

25. The method of claim 18, wherein the ECE inhibitor comprises a benzo[α

]naphtaeen chromophore.

26. The method of claim 18, wherein the benzo[α

]naphtaeen chromophore is 1,6,9,14-tertrahydoxy-3(2-hydroxypropyl)-7-methoxy-8,13-dioxo-5,6,8,13-tetrahydroenzo[α

]naphthacene-2-carboxylate-Na.

27. The method of claim 18, wherein the ECE inhibitor comprises a (S)-2-biphenyl-4yl-1-(1H-tetrazol-5-yl)ethyl-amino-methyl compound.

28. The method of claim 18, wherein the composition comprises one or more compounds selected from the group consisting of:

(a) a daleformis;

(b) a halistanol disulfate B;

(c) a phosphonic acid;

(d) hydroxamic acid; and

(e) a phosphoramidon.

29. The method of claim 18, wherein the composition comprises p-hydroxymercuribenzoate.

30. The method of claim 18, whereby administering the effective amount of one the ECE inhibitor is selected from a group consisting of systemic delivery, topical delivery, intraocular injection, intraocular perfusion, and retrobulbar injection.

31. The method of claim 18, whereby administering the effective amount of one the ECE inhibitor is selected from a group consisting of retrobulbar injection, intracameral delivery, and intravitreal delivery.

32. A method of treating an ocular disease in an animal, comprising:

administering to the animal an effective amount of a mixture comprising a plurality of compounds, wherein the plurality of compounds comprise one or more endothelin-(“

ET”

) antagonists and one or more endothelin-converting-enzyme (“

ECE”

) inhibitors.